The earnings call highlighted several positive developments, including a significant NDA submission, strong financial stability, and progress in clinical trials. However, these were counterbalanced by increased R&D expenses, a notable net loss, and challenges in clinical trial response rates.

Company Guidance -

Q2 2025

During Kura Oncology's Q1 2025 conference call, the company outlined significant milestones achieved and future guidance. Kura submitted a New Drug Application (NDA) for ziftomenib as a monotherapy in relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) and requested priority review, which could lead to a six-month FDA review period. The company reported cash, cash equivalents, and short-term investments of $703.2 million on a pro forma basis as of March 31, 2025, including a $45 million milestone payment from its Kyowa Kirin collaboration. Anticipated near-term milestones could bring an additional $375 million. Kura plans to present ziftomenib Phase 2 data at the ASCO Annual Meeting and is advancing its FTI program with preliminary data from multiple Phase 1 cohorts expected later this year. Furthermore, the company has initiated patient dosing for a Phase 1 trial of ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST). With a strategic focus on becoming a fully integrated organization, Kura is well-positioned to advance its pipeline and achieve critical value inflection points.

NDA Submission for Ziftomenib

Kura Oncology submitted a New Drug Application (NDA) for ziftomenib, their investigational menin inhibitor, as a monotherapy for relapsed or refractory NPM1-mutant AML. This marks a significant milestone in their clinical development efforts.

Strong Financial Position

Kura reported having $703.2 million in cash, cash equivalents, and short-term investments as of March 31, 2025. This financial stability is further supported by a $45 million milestone payment under their collaboration agreement with Kyowa Kirin.

Progress in Clinical Trials

Ziftomenib's Phase 2 registrational data were accepted for presentation at the ASCO Annual Meeting. Additionally, robust enrollment continues in the KOMET-007 and 008 studies evaluating ziftomenib in combination with various standards of care.

Farnesyl Transferase Inhibitor (FTI) Program Development

Kura's FTI program is advancing with plans to share preliminary clinical data from multiple Phase 1 cohorts later this year, highlighting the potential of FTIs in combination therapies.

Appointment of Senior Vice President

Samir Vattompadam joined Kura's leadership team as Senior Vice President, Global Program Leadership, bringing over 20 years of experience in the biotech and pharmaceutical industry.

Kura Oncology (KURA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KURA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 31, 2025	2025 (Q2)	-0.41 / -	-0.59	―	―	―
May 01, 2025	2025 (Q1)	-0.60 / -0.66	-0.59	-11.86% (-0.07)	―
Feb 26, 2025	2024 (Q4)	-0.64 / -0.22	-0.55	60.00% (+0.33)
Nov 07, 2024	2024 (Q3)	-0.63 / -0.63	-0.5	-26.00% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.63 / -0.59	-0.53	-11.32% (-0.06)
May 02, 2024	2024 (Q1)	-0.55 / -0.59	-0.5	-18.00% (-0.09)
Feb 27, 2024	2023 (Q4)	-0.55 / -0.55	-0.49	-12.24% (-0.06)
Nov 02, 2023	2023 (Q3)	-0.54 / -0.50	-0.53	5.66% (+0.03)
Aug 03, 2023	2023 (Q2)	-0.54 / -0.53	-0.52	-1.92% (-0.01)	―
May 10, 2023	2023 (Q1)	-0.54 / -0.50	-0.49	-2.04% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KURA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$6.49	$6.47	-0.31%
Feb 26, 2025	$7.77	$7.65	-1.54%
Nov 07, 2024	$17.77	$17.68	-0.51%
Aug 08, 2024	$19.12	$18.97	-0.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Kura Oncology (KURA) report earnings?

Kura Oncology (KURA) is schdueled to report earning on Jul 31, 2025, After Close (Confirmed).

What is Kura Oncology (KURA) earnings time?

Kura Oncology (KURA) earnings time is at Jul 31, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KURA EPS forecast?

KURA EPS forecast for the fiscal quarter 2025 (Q2) is -0.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing